Le Groupe Menarini et NewAmsterdam Pharma obtiennent l'autorisation de la Commission européenne pour Ubeslo® (obicetrapib en monothérapie) et Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)

The European Commission granted the first global marketing approvals for NewAmsterdam Pharma's oral LDL-C therapies Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe) for primary hypercholesterolemia and mixed dyslipidemia. Phase 3 trials showed LDL-C reductions of up to 40% for obicetrapib monotherapy and about 50% for the fixed-dose combination versus placebo, with placebo-comparable tolerability. Menarini holds exclusive European commercialization rights, while NewAmsterdam is eligible for tiered double-digit royalties up to approximately 25% of net sales and up to €833 million in potential milestones.

Analysis

NAMS shifts from a single-asset clinical valuation toward a commercial-royalty plus outcomes-readout valuation, but the near-term cash-flow contribution is likely modest: Menarini controls European pricing, reimbursement sequencing, and launch cadence, while NAMS receives a tiered royalty rather than product gross profit. The market should therefore value this primarily as regulatory de-risking and validation of the asset, not as an immediate revenue inflection. Any gap between the post-CHMP move and today’s reaction is likely limited, making country-level reimbursement wins—not broad EU authorization—the relevant 1-3 month catalysts.

Competitive pressure will center on the treatment step before injectable PCSK9 therapies. An effective oral fixed-dose option could take share from ESPR’s bempedoic-acid franchise in statin-intolerant patients and constrain incremental demand for NVS’s Leqvio, REGN’s Praluent and AMGN’s Repatha among patients whose LDL gap can be closed without an injection. However, payer economics are decisive: generic ezetimibe is nearly free, and obicetrapib needs a clearly favorable net price versus adding bempedoic acid or escalating directly to PCSK9 therapy to achieve broad uptake.

The underappreciated risk is that LDL lowering alone does not settle the CETP class’s historical credibility problem. PREVAIL is the principal 6-18 month value driver; a clean cardiovascular-outcomes result would materially expand the multiple and strengthen U.S. partnering/commercial leverage, whereas a neutral outcome could leave the product reimbursement-constrained despite regulatory approval. Falsification of a constructive thesis would be delayed major-market reimbursement, weak early prescription persistence, or any safety-language divergence across national labels.

Key Decisions for Investors

• Maintain or initiate a measured long NAMS only on post-approval consolidation rather than chase the opening move; size as a binary-outcomes biotech position. The next 1-3 month checkpoints are disclosed European launch timing, price/reimbursement decisions, and management’s cash-runway guidance.
• Use a pair framework: long NAMS / short ESPR in equal beta-adjusted dollars for 3-6 months, conditional on evidence that the fixed-dose product is priced competitively in major EU markets. The thesis is substitution in oral LDL intensification; exit if reimbursement restricts use to a narrow salvage population or ESPR demonstrates accelerating prescription growth.
• Do not short AMGN, REGN, or NVS on this development alone. Their injectable franchises remain protected in the highest-risk populations and by established reimbursement pathways; any near-term multiple impact should be negligible without proof of broad oral switching.
• Set an event-risk alert around PREVAIL timing and interim disclosures. A favorable outcomes signal would justify adding NAMS exposure and reassessing PCSK9 exposure; a delay, lower-than-expected event accrual, or adverse safety signal warrants reducing exposure before the definitive readout.